home / stock / ards / ards news

ARDS News and Press, Aridis Pharmaceuticals Inc. From 09/08/20

Stock Information
Company Name: Aridis Pharmaceuticals Inc.
Stock Symbol: ARDS
Market: NASDAQ
Website: aridispharma.com
Menu
ARDS ARDS Quote ARDS Short ARDS News ARDS Articles ARDS Message Board
Get ARDS Alerts

News, Short Squeeze, Breakout and More Instantly...
ARDS - Aridis Pharma on go with mid-stage study of AR-501 in cystic fibrosis

Aridis Pharmaceuticals (NASDAQ: ARDS ) has reached an agreement with the FDA to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF). More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
ARDS - Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501

SAN JOSE, Calif. , Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the U...

ARDS - Aridis Pharmaceuticals to Present at Upcoming Investor Conferences

SAN JOSE, Calif. , Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong , Ph.D....

ARDS - Aridis Pharmaceuticals EPS beats by $0.27, beats on revenue

Aridis Pharmaceuticals (NASDAQ: ARDS ) : Q2 GAAP EPS of -$0.47 beats by $0.27 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ARDS - Aridis Pharmaceuticals Announces Second Quarter 2020 Results

SAN JOSE, Calif. , Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the...

ARDS - Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

SAN JOSE, Calif. , June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong , Ph.D., Chi...

ARDS - Aridis's AR-501 shows positive effect in early-stage study

Aridis Pharmaceuticals's ( ARDS -3.0% ) AR-501 aerosols  demonstrated to be well tolerated, with no serious adverse events, in phase 1 portion of Phase1/2a trial. More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

ARDS - Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial

SAN JOSE, Calif. , June 22, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today positive results from the Phase 1 port...

ARDS - Aridis Pharmaceuticals to Discuss APEX(TM) in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th

SAN JOSE, Calif. , June 18, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it will participate in ...

ARDS - Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer

SAN JOSE, Calif. , June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed D...
Previous 10 Next 10